Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Grever, Michael ; Andritsos, Leslie ; Banerji, Versha ; Barrientos, Jacqueline C. ; Bhat, Seema ; Blachly, James S. ; Call, Timothy ; Cross, Matthew ; Dearden, Claire and Demeter, Judit , et al. (2021) In Leukemia 35(7). p.1864-1872
Abstract

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and... (More)

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia
volume
35
issue
7
pages
1864 - 1872
publisher
Nature Publishing Group
external identifiers
  • pmid:33947938
  • scopus:85105316132
ISSN
0887-6924
DOI
10.1038/s41375-021-01257-7
language
English
LU publication?
yes
id
364d7b51-fc39-4c07-ab44-39f691cb6bc2
date added to LUP
2021-06-01 13:37:06
date last changed
2025-02-09 11:59:24
@article{364d7b51-fc39-4c07-ab44-39f691cb6bc2,
  abstract     = {{<p>Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.</p>}},
  author       = {{Grever, Michael and Andritsos, Leslie and Banerji, Versha and Barrientos, Jacqueline C. and Bhat, Seema and Blachly, James S. and Call, Timothy and Cross, Matthew and Dearden, Claire and Demeter, Judit and Dietrich, Sasha and Falini, Brunangelo and Forconi, Francesco and Gladstone, Douglas E. and Gozzetti, Alessandro and Iyengar, Sunil and Johnston, James B. and Juliusson, Gunnar and Kraut, Eric and Kreitman, Robert J. and Lauria, Francesco and Lozanski, Gerard and Parikh, Sameer A. and Park, Jae and Polliack, Aaron and Ravandi, Farhad and Robak, Tadeusz and Rogers, Kerry A. and Saven, Alan and Seymour, John F. and Tadmor, Tamar and Tallman, Martin S. and Tam, Constantine S. and Tiacci, Enrico and Troussard, Xavier and Zent, Clive and Zenz, Thorsten and Zinzani, Pier Luigi and Wörmann, Bernhard}},
  issn         = {{0887-6924}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{1864--1872}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Leukemia}},
  title        = {{Hairy cell leukemia and COVID-19 adaptation of treatment guidelines}},
  url          = {{http://dx.doi.org/10.1038/s41375-021-01257-7}},
  doi          = {{10.1038/s41375-021-01257-7}},
  volume       = {{35}},
  year         = {{2021}},
}